| 0.7885 0.074 (10.37%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.06 | 1-year : | 1.22 |
| Resists | First : | 0.91 | Second : | 1.04 |
| Pivot price | 0.79  |
|||
| Supports | First : | 0.69 | Second : | 0.57 |
| MAs | MA(5) : | 0.74 |
MA(20) : | 0.82 |
| MA(100) : | 1.12 |
MA(250) : | 1.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21.2 |
D(3) : | 14 |
| RSI | RSI(14): 43.1 |
|||
| 52-week | High : | 2.18 | Low : | 0.69 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RNTX ] has closed above bottom band by 48.5%. Bollinger Bands are 52.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.79 - 0.79 | 0.79 - 0.8 |
| Low: | 0.71 - 0.72 | 0.72 - 0.72 |
| Close: | 0.78 - 0.79 | 0.79 - 0.79 |
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
Thu, 06 Aug 2026
RNTX PE Ratio & Valuation, Is RNTX Overvalued - Intellectia AI
Tue, 04 Aug 2026
Rein Therapeutics’ LTI-03 study published in Nature Communications By Investing.com - Investing.com UK
Tue, 04 Aug 2026
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications - GlobeNewswire
Tue, 04 Aug 2026
Rein's Inhaled LTI-03 Reduced Lung-Scarring Markers After 14 Days - Stock Titan
Fri, 31 Jul 2026
RNTX|Rein Therapeutics Inc|Price:0.737|Chg%:-0.031 - TradingKey
Thu, 30 Jul 2026
Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 86 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 5.3 (%) |
| Held by Institutions | 20.8 (%) |
| Shares Short | 879 (K) |
| Shares Short P.Month | 312 (K) |
| EPS | -1.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.1 % |
| Return on Equity (ttm) | -163.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.42 |
| PEG Ratio | 0 |
| Price to Book value | -0.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|